See all
 |
Articles: Drug/Product Alerts |
One-dose emergency contraceptive approved by FDA
American Pharmacists Association, 07/14/09
Free full text
Safety and Security
PharmExec, 07/14/09 Boston Scientific Announces European Approval for Its LATITUDE Patient Management System
Boston Scientific, 07/14/09
Free full text
FDA Approves Plan B One-Step, a New One-Pill Emergency Contraceptive
Teva Pharmaceutical Industries, 07/14/09
Free full text
New therapeutic option for heartburn
BayNews International, 07/13/09
Free full text
Pathways to Approval of Pediatric Cardiac Devices in the United States: Challenges and Solutions
Pediatrics, 07/10/09 Bayer submits first-in-class estradiol-based oral contraceptive for approval in the U.S.
BayNews International, 07/09/09
Free full text
Warfarin Interactions With Substances Listed in Drug Information Compendia and in the FDA-Approved Label for Warfarin Sodium
Clinical Pharmacology & Therapeutics, 07/09/09 Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
Watson Pharmaceuticals, 07/09/09
Free full text
Sanofi Gets Green Light on Blockbuster Heart Treatment
PharmExec, 07/09/09 Japanese Ministry of Health approves Rasilez, a first-in-class direct renin inhibitor, for the treatment of high blood pressure
Novartis, 07/09/09
Free full text
European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.'s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application
Cell Therapeutics, 07/08/09
Free full text
Synthon First Generic Filer for Xyzal Oral Solution
Synthon, 07/08/09
Free full text
Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex
Mylan, 07/08/09 Tolvaptan (Samsca): Vasopressin receptor antagonist approved for the treatment of clinically significant hypervolemic and euvolemic hyponatremia
Formulary, 07/07/09 European Commission approves statement on lipid improvement for Viramune label
Boehringer Ingelheim, 07/07/09
Free full text
KINAXO's Cellular Target Profiling reveals mTOR as a new target of Celebrex
b3c newswire, 07/07/09 Shire has filed a treatment protocol for velaglucerase alfa for Gaucher Disease
Shire, 07/07/09 Tadalafil (Adcirca): Phosphodiesterase type 5 inhibitor approved for the treatment of pulmonary arterial hypertension (WHO Group I)
Formulary, 07/06/09 Teva Announces Approval and Launch of Tri-Lo Sprintec Tablets
Teva Pharmaceutical Industries, 07/02/09
Free full text
|
|
Receive free subspecialty "5-minute updates" via email
|
|
Indexed Journals: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacist
more...
|
144 Available Pages
|
|